explore -WSS

explore

author：hotspot 2025-09-07 04:13:15 - browse：841

The Federal Trade Commission office glows softly inside, contrasting with the darkness outside — coverage from STAT — Adobe

Over the past two decades, hundreds of hospital mergers have escaped federal antitrust scrutiny and led to both higher prices and less competition, a new study shows.

But the study’s authors, and other researchers, believe the Federal Trade Commission’s hands often are tied. The agency simply doesn’t have enough money or people to crack down on all anticompetitive hospital deals, and some state laws shield hospital mergers from federal review completely.

“The resources available are just not commensurate with what the agency needs,” said Zack Cooper, an associate professor of health policy and economics at Yale University and one of the co-authors of the study. “This isn’t a story of the FTC not knowing what to do. I actually think they really know, very clearly, what to do. It’s a lack of resources, person power, and potentially willingness to do it.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

WSS

Insmed lung disease drug hits target in key Phase 3 trial

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Heat waves linked to early deliveries, preterm births in new study

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

With FDA staff opposed to Sarepta therapy, top official intervened

With FDA staff opposed to Sarepta therapy, top official intervened

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Do more moles mean more problems? Not so, says new study

Psychedelics group wrestles with new pharma identity

Death of patient in Alzheimer’s trial raises question of possible risks

Dobbs anniversary: the lost opportunity of abortion as health care

CDC concerned about possible undetected monkeypox spread in U.K.

United colonoscopy coverage change 'may cost lives,' doctors say

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Novavax promises a turnaround & Lilly roils the obesity market

Health insurers say they are turning to AI to cut costs, improve care

entertainment

Insmed lung disease drug hits target in key Phase 3 trial

First Opinion Podcast: What happens when kids become caregivers?

David Sabatini, ex

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

David Sabatini, ex

In areas with more Black doctors, Black people live longer

leisure time

hotspot

explore

focus